Skip to main content

Advertisement

SpringerLink
Log in

Vitamin D and Cardiovascular Disease

  • Prevention (L Sperling, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Vitamin D has received widespread attention for its potential role in preventing cardiovascular disease (CVD) and type 2 diabetes mellitus. Several epidemiological studies have suggested that individuals with low blood levels of vitamin D have increased risks of heart disease, stroke, hypertension, and diabetes. Yet, the revised 2011 Institute of Medicine report for intake of calcium and vitamin D, which was guided by skeletal health alone, concluded that the evidence that vitamin D prevents CVD, diabetes, or other cardiometabolic outcomes was inconsistent and inconclusive and did not meet criteria for establishing a cause and effect relationship [1•, 2]. This finding was consistent with an earlier systematic review conducted by the Agency for Healthcare Research and Quality (AHRQ) in 2009 [3•]. Ongoing clinical trials seek to address the effects of vitamin D supplementation on CVD and other nonskeletal outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin d from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53–8. This paper provides the clinician with a review of the current dietary guidelines.

    Article  PubMed  CAS  Google Scholar 

  2. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington: National Academies Press; 2011.

    Google Scholar 

  3. Chung M, Balk EM, Brendel M, et al. Vitamin D and calcium: a systematic review of health outcomes. Evidence report/technology assessment no.183. Agency for Healthcare Research and Quality. Rockville, MD Aug 2009. This paper is the AHRQ’s systemic review of the literature.

  4. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr. 2008;88(2):491S–9S.

    PubMed  CAS  Google Scholar 

  5. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81.

    Article  PubMed  CAS  Google Scholar 

  6. Chun RF, Adams JS, Hewison M. Back to the future: a new look at ‘old’ vitamin D. J Endocrinol. 2008;198(2):261–9.

    Article  PubMed  CAS  Google Scholar 

  7. Hewison M, Burke F, Evans KN, et al. Extra-renal 25-hydroxyvitamin D3-1[alpha]-hydroxylase in human health and disease. J Steroid Biochem Mol Biol. 2007;103(3–5):316–21.

    Article  PubMed  CAS  Google Scholar 

  8. Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008;4(2):80–90.

    Article  PubMed  CAS  Google Scholar 

  9. Zhou S, LeBoff MS, Glowacki J. Vitamin D metabolism and action in human bone marrow stromal cells. Endocrinology. 2010;151(1):14–22.

    Article  PubMed  CAS  Google Scholar 

  10. Holick MF, Siris ES, Binkley N, et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005;90(6):3215–24.

    Article  PubMed  CAS  Google Scholar 

  11. Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone. 2002;30(5):771–7.

    Article  PubMed  CAS  Google Scholar 

  12. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011;364(3):248–54.

    Article  PubMed  CAS  Google Scholar 

  13. Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA. Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2000–2004. Am J Clin Nutr. 2008;88(6):1519–27.

    Article  PubMed  CAS  Google Scholar 

  14. Cauley JA, Lacroix AZ, Wu L, et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med. 2008;149(4):242–50.

    PubMed  Google Scholar 

  15. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992;327(23):1637–42.

    Article  PubMed  CAS  Google Scholar 

  16. Chapuy MC, Pamphile R, Paris E, et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int. 2002;13(3):257–64.

    Article  PubMed  CAS  Google Scholar 

  17. LeBoff MS, Hawkes WG, Glowacki J, Yu-Yahiro J, Hurwitz S, Magaziner J. Vitamin D-deficiency and post-fracture changes in lower extremity function and falls in women with hip fractures. Osteoporos Int. 2008;19(9):1283–90.

    Article  PubMed  CAS  Google Scholar 

  18. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA. 1999;281(16):1505–11.

    Article  PubMed  CAS  Google Scholar 

  19. Pieper CF, Colon-Emeric C, Caminis J, et al. Distribution and correlates of serum 25-hydroxyvitamin D levels in a sample of patients with hip fracture. Am J Geriatr Pharmacother. 2007;5(4):335–40.

    Article  PubMed  CAS  Google Scholar 

  20. Moore CE, Murphy MM, Holick MF. Vitamin D intakes by children and adults in the United States differ among ethnic groups. J Nutr. 2005;135(10):2478–85.

    PubMed  CAS  Google Scholar 

  21. Harris SS. Vitamin D and African Americans. J Nutr. 2006;136(4):1126–9.

    PubMed  CAS  Google Scholar 

  22. Zadshir A, Tareen N, Pan D, Norris K, Martins D. The prevalence of hypovitaminosis D among US adults: data from the NHANES III. Ethn Dis. Autumn 2005;15(4 Suppl 5):S5-97-101.

    Google Scholar 

  23. Harris SS, Dawson-Hughes B. Reduced sun exposure does not explain the inverse association of 25-hydroxyvitamin D with percent body fat in older adults. J Clin Endocrinol Metab. 2007;92(8):3155–7.

    Article  PubMed  CAS  Google Scholar 

  24. Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167(11):1159–65.

    Article  PubMed  CAS  Google Scholar 

  25. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303(3):235–41.

    Article  PubMed  CAS  Google Scholar 

  26. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol. 2006;92(1):39–48.

    Article  PubMed  CAS  Google Scholar 

  27. Zittermann A, Koerfer R. Vitamin D in the prevention and treatment of coronary heart disease. Curr Opin Clin Nutr Metab Care. 2008;11(6):752–7.

    Article  PubMed  CAS  Google Scholar 

  28. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168(11):1174–80.

    Article  PubMed  CAS  Google Scholar 

  29. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–11.

    Article  PubMed  CAS  Google Scholar 

  30. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168(12):1340–9.

    Article  PubMed  CAS  Google Scholar 

  31. Anderson JL, May HT, Horne BD, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106(7):963–8.

    Article  PubMed  CAS  Google Scholar 

  32. Bassuk SS, Manson JE. Does vitamin D protect against cardiovascular disease? J Cardiovasc Transl Res. 2009;2(3):245–50.

    Article  PubMed  Google Scholar 

  33. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168(15):1629–37.

    Article  PubMed  Google Scholar 

  34. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med. 2010;152(5):315–23.

    PubMed  Google Scholar 

  35. Avenell A, Maclennan GS, Jenkinson DJ, et al. Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D3 and/or calcium (RECORD Trial). J Clin Endocrinol Metab. Nov 23 2011.

  36. Liu S, Song Y, Ford ES, Manson JE, Buring JE, Ridker PM. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care. 2005;28(12):2926–32.

    Article  PubMed  CAS  Google Scholar 

  37. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006;354(7):684–96.

    Article  PubMed  CAS  Google Scholar 

  38. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):669–83.

    Article  PubMed  CAS  Google Scholar 

  39. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. 2005;97(1–2):93–101.

    Article  PubMed  Google Scholar 

  40. Miyakoshi H, Aoki T, Hirasawa Y. Immunological effects of 1alpha-hydroxycholecalciferol (1alpha-OH-D3) and its metabolites. Clin Nephrol. 1981;16(3):119–25.

    PubMed  CAS  Google Scholar 

  41. D'Ambrosio D, Cippitelli M, Cocciolo MG, et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest. 1998;101(1):252–62.

    Article  PubMed  Google Scholar 

  42. Alroy I, Towers TL, Freedman LP. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol. 1995;15(10):5789–99.

    PubMed  CAS  Google Scholar 

  43. Muller K, Haahr PM, Diamant M, Rieneck K, Kharazmi A, Bendtzen K. 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine. 1992;4(6):506–12.

    Article  PubMed  CAS  Google Scholar 

  44. van Halteren AG, van Etten E, de Jong EC, Bouillon R, Roep BO, Mathieu C. Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). Diabetes. 2002;51(7):2119–25.

    Article  PubMed  Google Scholar 

  45. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000;164(5):2405–11.

    PubMed  CAS  Google Scholar 

  46. Griffin MD, Lutz WH, Phan VA, Bachman LA, McKean DJ, Kumar R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun. 2000;270(3):701–8.

    Article  PubMed  CAS  Google Scholar 

  47. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98(12):6800–5.

    Article  PubMed  CAS  Google Scholar 

  48. White JH. Vitamin D signaling, infectious diseases, and regulation of innate immunity. Infect Immun. 2008;76(9):3837–43.

    Article  PubMed  CAS  Google Scholar 

  49. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency and inflammation and their association with hemoglobin levels in chronic kidney disease. Am J Nephrol. 2009;30(1):64–72.

    Article  PubMed  CAS  Google Scholar 

  50. Shea MK, Booth SL, Massaro JM, et al. Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am J Epidemiol. 2008;167(3):313–20.

    Article  PubMed  Google Scholar 

  51. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83(4):754–9.

    PubMed  CAS  Google Scholar 

  52. Yamauchi Y, Tsunematsu T, Konda S, Hoshino T, Itokawa Y, Hoshizaki H. A double blind trial of alfacalcidol on patients with rheumatoid arthritis (RA). Ryumachi. 1989;29(1):11–24.

    PubMed  CAS  Google Scholar 

  53. Andjelkovic Z, Vojinovic J, Pejnovic N, et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol. 1999;17(4):453–6.

    PubMed  CAS  Google Scholar 

  54. Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol. 1996;134(6):1070–8.

    Article  PubMed  CAS  Google Scholar 

  55. Morimoto S, Yoshikawa K, Kozuka T, et al. Treatment of psoriasis vulgaris with oral 1 alpha,25-dihydroxyvitamin D3–report of two cases. J Dermatol. 1987;14(1):59–62.

    PubMed  CAS  Google Scholar 

  56. El-Azhary RA, Peters MS, Pittelkow MR, Kao PC, Muller SA. Efficacy of vitamin D3 derivatives in the treatment of psoriasis vulgaris: a preliminary report. Mayo Clin Proc. 1993;68(9):835–41.

    PubMed  CAS  Google Scholar 

  57. Elst EF, Van Suijlekom-Smit LW, Oranje AP. Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatr Dermatol. 1999;16(1):53–8.

    Article  PubMed  CAS  Google Scholar 

  58. Bjorkman MP, Sorva AJ, Tilvis RS. C-reactive protein and fibrinogen of bedridden older patients in a 6-month vitamin D supplementation trial. J Nutr Health Aging. 2009;13(5):435–9.

    Article  PubMed  CAS  Google Scholar 

  59. Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension. 2008;52(2):249–55.

    Article  PubMed  CAS  Google Scholar 

  60. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229–38.

    PubMed  CAS  Google Scholar 

  61. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29(6):726–76.

    Article  PubMed  CAS  Google Scholar 

  62. Tarcin O, Yavuz DG, Ozben B, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab. 2009;94(10):4023–30.

    Article  PubMed  CAS  Google Scholar 

  63. Kahonen M, Nappi S, Jolma P, et al. Vascular influences of calcium supplementation and vitamin D-induced hypercalcemia in NaCl-hypertensive rats. J Cardiovasc Pharmacol. 2003;42(3):319–28.

    Article  PubMed  Google Scholar 

  64. Wakasugi M, Noguchi T, Inoue M, et al. Vitamin D3 stimulates the production of prostacyclin by vascular smooth muscle cells. Prostaglandins. 1991;42(2):127–36.

    Article  PubMed  CAS  Google Scholar 

  65. Wong MS, Delansorne R, Man RY, Vanhoutte PM. Vitamin D derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 2008;295(1):H289–96.

    Article  PubMed  CAS  Google Scholar 

  66. Zittermann A, Koerfer R. Protective and toxic effects of vitamin D on vascular calcification: clinical implications. Mol Aspects Med. 2008;29(6):423–32.

    Article  PubMed  CAS  Google Scholar 

  67. Zittermann A, Schleithoff SS, Gotting C, et al. Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail. 2008;10(3):321–7.

    Article  PubMed  CAS  Google Scholar 

  68. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008;74(2):170–9.

    Article  PubMed  CAS  Google Scholar 

  69. Qiao G, Kong J, Uskokovic M, Li YC. Analogs of 1alpha,25-dihydroxyvitamin D(3) as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol. 2005;96(1):59–66.

    Article  PubMed  CAS  Google Scholar 

  70. Deb DK, Chen Y, Zhang Z, et al. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway. Am J Physiol Renal Physiol. 2009;296(5):F1212–8.

    Article  PubMed  CAS  Google Scholar 

  71. Freundlich M, Quiroz Y, Zhang Z, et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008;74(11):1394–402.

    Article  PubMed  CAS  Google Scholar 

  72. Resnick LM, Muller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med. 1986;105(5):649–54.

    PubMed  CAS  Google Scholar 

  73. Burgess ED, Hawkins RG, Watanabe M. Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am J Hypertens. 1990;3(12 Pt 1):903–5.

    PubMed  CAS  Google Scholar 

  74. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet Med. 2008;25(3):320–5.

    Article  PubMed  CAS  Google Scholar 

  75. Shapses SA, Manson JE. Vitamin D and prevention of cardiovascular disease and diabetes: why the evidence falls short. JAMA. 2011;305(24):2565–6.

    Article  PubMed  CAS  Google Scholar 

  76. Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology. 1986;119(1):84–90.

    Article  PubMed  CAS  Google Scholar 

  77. Chertow BS, Sivitz WI, Baranetsky NG, Clark SA, Waite A, Deluca HF. Cellular mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology. 1983;113(4):1511–8.

    Article  PubMed  CAS  Google Scholar 

  78. Ismail A, Namala R. Impaired glucose tolerance in vitamin D deficiency can be corrected by calcium. J Nutr Biochem. 2000;11(3):170–5.

    Article  PubMed  CAS  Google Scholar 

  79. Nyomba BL, Bouillon R, De Moor P. Influence of vitamin D status on insulin secretion and glucose tolerance in the rabbit. Endocrinology. 1984;115(1):191–7.

    Article  PubMed  CAS  Google Scholar 

  80. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79(5):820–5.

    PubMed  CAS  Google Scholar 

  81. Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract. 1995;27(3):181–8.

    Article  PubMed  CAS  Google Scholar 

  82. Liu E, Meigs JB, Pittas AG, et al. Plasma 25-hydroxyvitamin d is associated with markers of the insulin resistant phenotype in nondiabetic adults. J Nutr. 2009;139(2):329–34.

    PubMed  CAS  Google Scholar 

  83. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990–2000. Diabetes. 2008;57(10):2619–25.

    Article  PubMed  CAS  Google Scholar 

  84. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92(6):2017–29.

    Article  PubMed  CAS  Google Scholar 

  85. Avenell A, Cook JA, MacLennan GS, McPherson GC. Vitamin D supplementation and type 2 diabetes: a substudy of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing. 2009;38(5):606–9.

    Article  PubMed  Google Scholar 

  86. von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient—a randomised, placebo-controlled trial. Br J Nutr. 2010;103(4):549–55.

    Article  Google Scholar 

  87. Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr. 2009;89(5):1321–7.

    Article  PubMed  CAS  Google Scholar 

  88. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007;30(4):980–6.

    Article  PubMed  CAS  Google Scholar 

  89. Shankar A, Sabanayagam C, Kalidindi S. Serum 25-hydroxyvitamin d levels and prediabetes among subjects free of diabetes. Diabetes Care. 2011;34(5):1114–9.

    Article  PubMed  CAS  Google Scholar 

  90. Ahmed W, Khan N, Glueck CJ, et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res J Lab Clin Med. 2009;153(1):11–6.

    CAS  Google Scholar 

  91. Bell DS. Resolution of statin-induced myalgias by correcting vitamin D deficiency. South Med J. 2010;103(7):690–2.

    Article  PubMed  Google Scholar 

  92. Lee P, Greenfield JR, Campbell LV. Vitamin D insufficiency—a novel mechanism of statin-induced myalgia? Clin Endocrinol (Oxf). 2009;71(1):154–5.

    Article  CAS  Google Scholar 

  93. Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem. 2002;277(28):25125–32.

    Article  PubMed  CAS  Google Scholar 

  94. Thummel KE, Brimer C, Yasuda K, et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol. 2001;60(6):1399–406.

    PubMed  CAS  Google Scholar 

  95. Bhattacharyya S, Bhattacharyya K, Maitra A. Possible mechanisms of interaction between statins and vitamin D. QJM Mon J Assoc Physicians. 2012;105(5):487–91.

    Article  CAS  Google Scholar 

  96. Defay R, Astruc ME, Roussillon S, Descomps B, Crastes de Paulet A. DNA synthesis and 3-hydroxy-3-methylglutaryl CoA reductase activity in PHA stimulated human lymphocytes: a comparative study of the inhibitory effects of some oxysterols with special reference to side chain hydroxylated derivatives. Biochem Biophys Res Commun. 1982;106(2):362–72.

    Article  PubMed  CAS  Google Scholar 

  97. Bittner V, Wenger N, Waters D, DeMicco DA, Messig M, LaRosa J. Vitamin D levels are not related to myalgias in statin-treated patients with stable coronary disease. J Am Coll Cardiol. 2010;55(Abstract. A177.E1659).

  98. Manson JE, Bassuk SS, Lee IM, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33(1):159–71. This paper provides a detailed rationale of the VITAL trial..

    Article  PubMed  CAS  Google Scholar 

  99. American Cancer Society. Cancer facts & figures for African AMericans 2009–2010. Atlanta: American Cancer Society; 2009.

    Google Scholar 

  100. Institute of Medicine Food and Nutrition Board. Dietary reference intakes: calcium, phosphorous, magnesium vitamin D and fluoride. Washington: National Academies Press; 1999.

    Google Scholar 

  101. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84(1):18–28.

    PubMed  CAS  Google Scholar 

  102. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int. 2005;16(7):713–6.

    Article  PubMed  CAS  Google Scholar 

  103. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98(7):451–9.

    Article  PubMed  CAS  Google Scholar 

  104. Aloia JF, Patel M, Dimaano R, et al. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr. 2008;87(6):1952–8.

    PubMed  CAS  Google Scholar 

Download references

Disclosures

Dr. Jacqueline S. Danik is the medical safety officer and Dr. JoAnn E. Manson is the principal investigator of the VITamin D and OmegA-3 TriaL (VITAL; CA138962), a National Institutes of Health sponsored trial of vitamin D supplementation in the prevention of cancer and cardiovascular disease.

Author information

Authors and Affiliations

  1. Division of Preventive Medicine, Brigham and Women’s Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA, 02215, USA

    Jacqueline S. Danik MD, DrPH & JoAnn E. Manson MD, DrPH

Authors
  1. Jacqueline S. Danik MD, DrPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. JoAnn E. Manson MD, DrPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacqueline S. Danik MD, DrPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Danik, J.S., Manson, J.E. Vitamin D and Cardiovascular Disease. Curr Treat Options Cardio Med 14, 414–424 (2012). https://doi.org/10.1007/s11936-012-0183-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-012-0183-8

Keywords

Search

Navigation